WO2016184829A1 - Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases - Google Patents

Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases Download PDF

Info

Publication number
WO2016184829A1
WO2016184829A1 PCT/EP2016/060945 EP2016060945W WO2016184829A1 WO 2016184829 A1 WO2016184829 A1 WO 2016184829A1 EP 2016060945 W EP2016060945 W EP 2016060945W WO 2016184829 A1 WO2016184829 A1 WO 2016184829A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
bis
fluoro
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/060945
Other languages
French (fr)
Inventor
Mike TROWER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerre Therapeutics Ltd
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56008636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016184829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HRP20192132TT priority Critical patent/HRP20192132T1/en
Priority to SI201630503T priority patent/SI3297631T1/en
Priority to CN201680025842.XA priority patent/CN107635557A/en
Priority to BR112017024852-2A priority patent/BR112017024852B1/en
Priority to ES16723107T priority patent/ES2753539T3/en
Priority to AU2016264034A priority patent/AU2016264034B2/en
Priority to RU2017134908A priority patent/RU2743206C2/en
Priority to LT16723107T priority patent/LT3297631T/en
Priority to CN202210025858.8A priority patent/CN114306335A/en
Priority to KR1020177036005A priority patent/KR102704783B1/en
Priority to RS20191505A priority patent/RS59608B1/en
Priority to CA2984591A priority patent/CA2984591A1/en
Priority to DK16723107T priority patent/DK3297631T3/en
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Priority to MX2017012720A priority patent/MX377052B/en
Priority to PL16723107T priority patent/PL3297631T3/en
Priority to EP16723107.5A priority patent/EP3297631B1/en
Priority to CN202210025860.5A priority patent/CN114306347A/en
Priority to EP19186140.0A priority patent/EP3574907B1/en
Priority to CN202210026259.8A priority patent/CN114272242A/en
Priority to SM20190719T priority patent/SMT201900719T1/en
Priority to JP2017554079A priority patent/JP6902682B2/en
Publication of WO2016184829A1 publication Critical patent/WO2016184829A1/en
Anticipated expiration legal-status Critical
Priority to CY20191101087T priority patent/CY1122180T1/en
Priority to AU2020201074A priority patent/AU2020201074B2/en
Priority to LTPA2026506C priority patent/LTPA2026506I1/lt
Priority to FIC20260003C priority patent/FIC20260003I1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • This invention relates to a method of treatment of sex-hormone dependent diseases, in a mammal, for which gonadotropin suppression and/or androgen suppression is desired.
  • Gonadotropin and /or androgen suppression is achieved according to this invention by administration of a dual neurokinin-1 (NK-1) receptor antagonist and neurokinin-3 (NK-3) receptor antagonist (herein called dual NK-l/NK-3 receptor antagonists).
  • NK-1 receptor antagonist and NK-3) receptor antagonist herein called dual NK-l/NK-3 receptor antagonists.
  • Suitable dual NK-l/NK-3 receptor antagonists useful in this invention are represented by the compounds described herein.
  • Androgens are generally known as the male sex hormones.
  • the androgenic hormones are steroids, which are produced in adult males by the testes and adult females by ovarian theca cells; and a lesser amount by the cortex of the adrenal gland or can be synthesized in the laboratory. Androgenic steroids play an important role in many physiologic processes, including the development and maintenance of male sexual characteristics such as muscle and bone mass, prostate growth, spermatogenesis, and the male hair pattern
  • the endogenous steroidal androgens include testosterone and dihydrotestosterone ("DHT").
  • Testosterone is the principal steroid secreted by the testes and is the primary circulating androgen found in the plasma of adult males. Under normal physiological circumstances males produce much more testosterone than females. Testosterone is converted to DHT by the enzyme 5-alpha-reductase in many peripheral tissues. DHT is thus thought to serve as the intracellular mediator for most androgen actions.
  • the gonadotropin-releasing hormone also referred to as luteinizing hormone-releasing hormone (LHRH)
  • LHRH luteinizing hormone-releasing hormone
  • the hormone is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH).
  • LH released from the pituitary gland is primarily responsible for the regulation of gonadal steroid production in both sexes, whereas FSH regulates spermatogenesis in males and follicular development in females.
  • these diseases or disorders include, but are not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, breast cancer, testicular cancer, androgen dependent acne, hypertrichosis, seborrhoea, male pattern baldness and precocious puberty in boys.
  • BPH benign prostatic hyperplasia
  • metastatic prostatic carcinoma breast cancer
  • testicular cancer testicular cancer
  • androgen dependent acne hypertrichosis
  • seborrhoea seborrhoea
  • male pattern baldness and precocious puberty in boys.
  • PCOS Polycystic Ovarian Syndrome
  • endometriosis adenomyosis
  • uterine fibroids heavy menstrual bleeding
  • hirsutism androgen dependent acne
  • seborrhoea female androgenetic alopecia and hypertrichosis
  • gonadal steroid- dependent neoplasm cowast cancer, ovary cancer, etc.
  • gonadotropin-producing pituitary adenoma premenstrual syndrome and sterility
  • Other related conditions affecting women are pre-eclampsia and pregnancy prevention (contraception), and for both sexes, hidradenitis suppurativa and hot flushes.
  • gonadotropin and androgen suppression also called androgen deprivation
  • gonadotropin and androgen suppression is accompanied by a variety of undesirable clinical conditions and symptoms.
  • gonadotrophin releasing hormone (GnRH) agonists these initially cause a flare of increased androgen production that in patients with sex-hormone sensitive cancers may cause a short term increase in tumour growth and if the cancer has spread to the bone it may result in pain.
  • GnRH gonadotrophin releasing hormone
  • These agents are also injected so there could be soreness, swelling and redness at the injection site.
  • GnRH antagonists are for example reduced or absent libido, impotence, shrinkage of testicles and penis, hot flushes, breast tenderness or growth of breasts, osteoporosis, anemia, cognitive reduction, muscle mass loss, weight gain, fatigue, elevated cholesterol and depression.
  • Cyproterone acetate can cause oligomenorrhea (females only), melasma, fluid retention, nausea and vomiting; this drug is also in rarer cases associated with liver hepatotoxicity and clotting disorders. Flutamide administration may lead to breast tenderness, gastrointestinal upset, hot flashes, and decreased libido; it has a serious potential side-effect of hepatotoxicity. Females taking combined oral contraceptives may experience metrorrhagia, nausea, vomiting, breast tenderness and headaches; and more rarely blood clots, myocardial infarctions, stroke, abnormal lipid indices, glucose intolerance and hypertension.
  • compositions and treatment regimens which provide the beneficial effects of androgen and/or gonadotropins suppression or abrogation, without the deleterious side-effects associated with the current treatments for sex-hormone dependent diseases.
  • Tachykinins belong to a family of short peptides that are widely distributed in the mammalian central and peripheral nervous system (Bertrand and Geppetti, Trends Pharmacol. Sci. 17: 255-259 (1996)). They share the common C-terminal sequence Phe-Xaa-Gly-Leu-Met-NH2.
  • the three major tachykinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB) with preferential affinity for respectively three distinct receptor subtypes, termed NK-1, NK-2, and NK-3.
  • a dual NK-l/NK-3 receptor antagonist according to the present invention would be useful in the treatment of sex-hormone dependent diseases in which decreased levels of androgens and gonadotropins are desired.
  • the present invention relates to the novel use of dual NK-l/NK-3 receptor antagonists to achieve gonadotropin and/or androgen suppression in mammals.
  • dual NK-l/NK-3 receptor antagonists are administered for the treatment of diseases which are caused by abnormal levels of androgens, particularly testosterone.
  • the compounds described herein by reference are particularly useful according to this invention.
  • the solution provided by the present invention is the use of dual NK- l/NK-3 receptor antagonists in the treatment of sex-hormone dependent diseases.
  • the invention provides a method of treatment of sex-hormone dependent diseases comprising administering to a human in need thereof an effective amount of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
  • the invention provides the use of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases.
  • the invention provides dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases.
  • the invention provides a method for providing oral contraception, said method comprising administering to the patient an effective amount of dual NK-l/NK-3 receptor antagonists.
  • dual NK-l/NK-3 receptor antagonists for the production of a drug for oral contraception.
  • the instant invention is in a method of treatment of sex-hormone dependent diseases which are affected, or exacerbated by, elevated and/or abnormal levels of gonadotropins and/or androgens.
  • the invention relates to a method of suppressing gonadotropin and/or androgen blood levels by administering an effective amount of a dual NK- l/NK-3 receptor antagonist.
  • the compounds defined herein exhibit the ability to suppress gonadotropin and/or androgen production, and in particular, are effective in reversibly lowering blood levels of LH and the androgen testosterone.
  • sex hormone-dependent disease means a disease which is exacerbated by, or caused by, excessive, inappropriate or unregulated sex hormone production.
  • BPH benign prostatic hyperplasia
  • metastatic prostatic carcinoma testicular cancer
  • breast cancer breast cancer
  • androgen dependent acne seborrhoea
  • hypertrichosis male pattern baldness and in boys precocious puberty.
  • Example of such diseases in women include but not limited to endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, hormone-dependent cancers (ovarian cancer, breast cancer), hyperandrogenism, hirsutism, hypertrichosis, female androgenetic alopecia, androgen dependent acne, seborrhoea, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with hyperplasia of luteinized theca cells in ovarian stroma), other manifestations of high intraovarian androgen concentrations (e.g.
  • follicular maturation arrest atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen- producing tumor (virilizing ovarian or adrenal tumor) and osteoporosis.
  • women other examples are pre-eclampsia and for both sexes, hidradenitis suppurativa and hot flushes.
  • a dual NK-l/NK-3 receptor antagonist refers to a compound that shows in a single molecule simultaneously affinity to both NK-1 and NK-3 receptors.
  • estrogen is used herein to mean steroids that encourage the development of male sex characteristics and include the steroid derivatives of androstane including testosterone, dihydrotestosterone, androstenedione, and analogs.
  • gonadotropin suppression refers to the reduction in the production or synthesis of one or more naturally occurring gonadotropins, including lutinizing hormone and follicle-stimulating hormone.
  • androgen suppression refers to an effective amount of a dual NK-l/NK-3 receptor antagonist, which will cause a decrease in the in vivo levels of the androgen to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated androgen production.
  • hot flushes is interchangeable with the term “hot flashes” and with the term “vasomotor symptoms” and intended to have the same meaning.
  • treatment refers to obtaining a desired pharmacologic, physiologic, dermatologic or cosmetic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a condition or disease or disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a condition or disease or disorder and/or adverse symptom or effect attributable to the condition or disease or disorder.
  • Treatment covers any treatment of a condition or disease in a mammal, particularly in a human, and includes: (a) preventing the condition or disease, disorder or symptom thereof from occurring in a subject which may be predisposed to the condition or disease or disorder but has not yet been diagnosed as having it; (b) inhibiting the condition or disease, disorder or symptom thereof, such as, arresting its development; and (c) relieving, alleviating or ameliorating the condition or disease or disorder or symptom thereof, such as, for example, causing regression of the condition or disease or disorder or symptom thereof.
  • the term "effective amount” means that amount of a drug or a therapeutic agent or a pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher, clinician or veterinarian.
  • pharmaceutically acceptable excipient or “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition.
  • each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
  • each excipient must of course be pharmaceutically-acceptable e.g. of sufficiently high purity.
  • pharmaceutically acceptable salts means salts suitable for medical applications having a pharmaceutically acceptable anion or cation.
  • the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, abnormal puberty, uterine fibrosis, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian or adrenal tumor, or osteoporosis, comprising administering to a human in need thereof an effective
  • NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
  • the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis
  • the present invention provides dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, abnormal puberty, uterine fibrosis, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing
  • BPH benign pro
  • the present invention provides dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunction
  • BPH benign
  • the invention provides the use of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, abnormal puberty, uterine fibrosis, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility
  • BPH benign pro
  • the invention provides the use of a dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, , hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation
  • BPH benign pro
  • the sex-hormone dependent diseases according to the invention are selected from hirsutism, endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
  • PCOS polycystic ovary syndrome
  • NK-l/NK-3 receptor antagonists as described in, and made according to WO2004056799, WO2004056805, WO2005002577, WO2005097794, WO2006013050, WO2007028654,
  • Preferred pyridine derivatives of WO2006013050 for use herein are as follows:
  • Preferred pyrrolidine derivatives of WO2008128891 for use herein are as follows:
  • Preferred pyrazolopyridine derivatives of WO2011131571 for use herein are as follows:
  • WO2011023733 discloses compound of formula A in a crystalline anhydrate form (Form 1), having certain characteristic 2 theta angles occurring at 4.3+0.1, 7.9+0.1, 9.8+0.1, 10.7+0.1, 10.8+0.1, 13.3+0.1, 14.0+0.1, 15.1+0.1degrees, which correspond respectively to d-spacing at 20.4, 11.1, 9.0, 8.3, 8.2, 6.6, 6.3 and 5.9 Angstroms (A).
  • the invention provides
  • the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor,
  • BPH benign
  • the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of androgen dependent hirsutism, female androgenetic , endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes, which comprises administering to a human in need thereof an effective amount comprising administering to a human in need thereof an effective amount of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
  • sex- hormone dependent diseases selected from the group consisting of androgen dependent hirsutism, female androgenetic , endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes
  • the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of androgen dependent hirsutism, female androgenetic endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes, which comprises administering to a human in need thereof an effective amount of 2-[3,5-Bis(trifluoromethyl)phenyl] -N- ⁇ 4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] -3- pyridinyl ⁇ -N,2-dimethylpropanamide; (2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro
  • the compound according to the invention is 2- [3,5-Bis(trifluoromethyl)phenyl] -N- ⁇ 4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] -3-pyridinyl ⁇ - N,2-dimethylpropanamide as anhydrous crystalline Form 1 for use in the treatment of endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
  • PCOS polycystic ovary syndrome
  • the compound according to the invention is 2- [3,5-Bis(trifluoromethyl)phenyl] -N- ⁇ 4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] -3-pyridinyl ⁇ - N,2-dimethylpropanamide as anhydrous crystalline Form 1 for use in the treatment of hot flushes.
  • GnRH gonadotropin-releasing hormone
  • dual NK-l/NK-3 receptor antagonists can be used alone or in combination with estrogen and progestin as contraceptives.
  • the present invention provides a method for providing oral contraception, said method comprising administering to the patient an effective amount of dual NK-l/NK-3 receptor antagonists.
  • Compounds for use for oral contraception include dual NK-l/NK-3 receptor antagonists as described in, and made according to WO2004056799, WO2004056805, WO2005002577, WO2005097794, WO2006013050,
  • Preferred pyridine derivatives of WO2006013050 for use for oral contraception are those disclosed on pages 8 and 9, lines 10-45 and lines 1-15 respectively of the present specification.
  • Preferred pyrrolidine derivatives of WO2008128891 for use for oral contraception are those disclosed on page 9, lines 15-43 of the present specification.
  • Preferred pyrazolopyridine derivatives of WO201131571 for use for oral contraception are those disclosed from page 9, line 47 to page 11, line 6 of the present specification.
  • Particularly preferred compounds for use for oral contraception are:
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a dual NK-l/NK-3 receptor antagonist or a compound described above, a pharmaceutically acceptable salt or crystalline forms thereof, and a pharmaceutically acceptable carrier.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a dual NK-l/NK-3 receptor antagonist or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in the treatment of sex hormone-dependent diseases.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising 2-[3,5-Bis(trifluoromethyl)phenyl]-N- ⁇ 4-(4-fluoro-2- methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l- c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl ⁇ -N,2-dimethylpropanamide or crystalline anhydrate forms thereof and a pharmaceutically acceptable carrier for use in the treatment of of sex hormone-dependent diseases.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising 2-[3,5-Bis(trifluoromethyl)phenyl]-N- ⁇ 4-(4-fluoro-2- methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l- c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl ⁇ -N,2-dimethylpropanamide or crystalline anhydrate forms thereof and a pharmaceutically acceptable carrier for use in the treatment hirsutism, endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
  • PCOS polycystic ovary syndrome
  • the present invention provides a drug containing a dual NK-l/NK-3 receptor antagonist and a pharmaceutically acceptable carrier.
  • the present invention provides a drug containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N- ⁇ 4-(4-fluoro-2-methylphenyl)
  • Such a medicament, and a composition of this invention may be prepared by admixture of a compound of the invention with an appropriate pharmaceutically acceptable carrier. It may contain a diluent, binder, filler, disintegrant, flavoring agent, colouring agent, lubricant or preservative in conventional manner.
  • a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarian fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
  • the suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • the compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.
  • the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release ofthe active ingredient.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • compositions may contain conventional excipients such as binding agents, for example syrup, acacia, gelatine, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatine, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinyl-pyrroli
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk.
  • Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the composition may also be in the form of an ingestible capsule, for example of gelatine containing the compound, if desired with a carrier or other excipients.
  • compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatine, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavoring or colour
  • compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e. g. sterile pyrogenic-free water or a parenterally acceptable oil or a mixture of liquids.
  • a pharmaceutically acceptable liquid e. g. sterile pyrogenic-free water or a parenterally acceptable oil or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the compounds of this invention may also be administered by inhalation, via the nasal or oral routes.
  • administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
  • Preferred spray formulations comprise micronized compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles.
  • the compound particle size is from about 2 to 10 microns.
  • a further mode of administration of the compounds of the invention comprises transdermal delivery utilizing a skin-patch formulation.
  • a preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient.
  • pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.
  • compositions according to the present subject matter may be performed according to methods known in the art.
  • pharmaceutically acceptable auxiliaries as well as further suitable diluents, flavourings, sweetening agents, colouring agents etc. may be used, depending on the intended mode of administration as well as particular characteristics of the active compound to be used, such as solubility, bioavailability etc.
  • Any non-toxic, inert, and effective topical, oral, etc. pharmaceutically acceptable carrier may be used to formulate the compositions described herein.
  • the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration.
  • An effective dose will generally contain from 1 mg to 250 mg and preferably will contain from 10 mg to 220 mg, in particular 30 mg to 200 mg.
  • composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 30 mg to 200 mg.
  • the unit dose will contain from 10 to 100 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily doses.
  • the compounds of the invention or pharmaceutically acceptable salts thereof and the other pharmaceutically active agent(s) may be administered together in a fix combination or separately (i.e. non fix combination).
  • Suitable therapeutic agents which may be used in combination of the compounds of the invention or pharmaceutically acceptable salts thereof include agonists of Gonadotropin-releasing hormone (GnRH) such as nafarelin, buserelin, goserelin and leuprorelin; antagonists of the Gonadotropin-releasing hormone (GnRH) such as degarelix, ganirelix, cetrorelix, abarelix and elagolix; 5- alpha-reductase inhibitors such as dutasteride and finasteride; combined androgen receptor antagonists/ 5-alpha-reductase inhibitors such as spironolactone; anti-androgens such as cyproterone acetate and flutamide; combined (estrogen with a progestin) oral contraceptives such as estrogen with either norgestimate, or norethindrone, or drospirenone; progesterone receptor modulators such as ulipristal acetate.
  • Compound A 2-[3,5-Bis(trifluoromethyl)phenyl] -N- ⁇ 4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)- -(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(l//)-yl] -3-pyridinyl ⁇ - N,2-dimethylpropanamide(hereinafter Compound A) was administered both as single and repeat ascending doses in male human volunteers (HV) and the effect of Compound A on the levels of testosterone was assessed
  • HV serum testosterone levels were determined as described in Table 1.
  • Part A of this study comprised 3 cohorts that investigated the safety, tolerability and PK of escalating multiple daily doses of Compound A. Information on these cohorts is as follows: Cohorts 1 and 2 received Compound A for 14 days; with a follow-up 7 to 14 days after their last dose. Testosterone levels in both cohorts were measured pre-dose on Day 1, on Day 15 and at follow-up.
  • Cohort 3 also received Compound A over a repeat treatment period of 14 days; with a follow-up 7-14 days after their last dose. Testosterone levels were measured in this cohort pre-dose on Day-1 and pre-dose on Day 14, and at follow- up.
  • SD standard deviation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Multicomponent Fibers (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.

Description

DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SEX-HORMONE-DEPENDENT DISEASES
FIELD OF THE INVENTION
This invention relates to a method of treatment of sex-hormone dependent diseases, in a mammal, for which gonadotropin suppression and/or androgen suppression is desired. Gonadotropin and /or androgen suppression is achieved according to this invention by administration of a dual neurokinin-1 (NK-1) receptor antagonist and neurokinin-3 (NK-3) receptor antagonist (herein called dual NK-l/NK-3 receptor antagonists). Suitable dual NK-l/NK-3 receptor antagonists useful in this invention are represented by the compounds described herein.
BACKGROUND OF THE INVENTION
Androgens are generally known as the male sex hormones. The androgenic hormones are steroids, which are produced in adult males by the testes and adult females by ovarian theca cells; and a lesser amount by the cortex of the adrenal gland or can be synthesized in the laboratory. Androgenic steroids play an important role in many physiologic processes, including the development and maintenance of male sexual characteristics such as muscle and bone mass, prostate growth, spermatogenesis, and the male hair pattern The endogenous steroidal androgens include testosterone and dihydrotestosterone ("DHT").
Testosterone is the principal steroid secreted by the testes and is the primary circulating androgen found in the plasma of adult males. Under normal physiological circumstances males produce much more testosterone than females. Testosterone is converted to DHT by the enzyme 5-alpha-reductase in many peripheral tissues. DHT is thus thought to serve as the intracellular mediator for most androgen actions.
The gonadotropin-releasing hormone (GnRH), also referred to as luteinizing hormone-releasing hormone (LHRH), is a decapeptide that plays a key role in human reproduction. The hormone is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). LH released from the pituitary gland is primarily responsible for the regulation of gonadal steroid production in both sexes, whereas FSH regulates spermatogenesis in males and follicular development in females.
It has been found that androgen and/or gonadotropin suppression or abrogation may result in beneficial effects, in a number of diseases and clinical applications, in males and in females.
In men these diseases or disorders, include, but are not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, breast cancer, testicular cancer, androgen dependent acne, hypertrichosis, seborrhoea, male pattern baldness and precocious puberty in boys. In women, androgen and/or gonadotropin suppression or abrogation, has been shown to be therapeutic in clinical settings, such as, for example, in treating Polycystic Ovarian Syndrome (PCOS), endometriosis, adenomyosis, uterine fibroids, heavy menstrual bleeding, hirsutism, androgen dependent acne, seborrhoea, female androgenetic alopecia and hypertrichosis, gonadal steroid- dependent neoplasm (breast cancer, ovary cancer, etc.), gonadotropin-producing pituitary adenoma, premenstrual syndrome and sterility (e.g. assisted reproductive techniques such as in vitro fertilization?. Other related conditions affecting women are pre-eclampsia and pregnancy prevention (contraception), and for both sexes, hidradenitis suppurativa and hot flushes.
As is the case in male and female subjects, however, gonadotropin and androgen suppression (also called androgen deprivation) is accompanied by a variety of undesirable clinical conditions and symptoms. For males receiving gonadotrophin releasing hormone (GnRH) agonists these initially cause a flare of increased androgen production that in patients with sex-hormone sensitive cancers may cause a short term increase in tumour growth and if the cancer has spread to the bone it may result in pain. These agents are also injected so there could be soreness, swelling and redness at the injection site. Other side effects that are also associated with GnRH antagonists are for example reduced or absent libido, impotence, shrinkage of testicles and penis, hot flushes, breast tenderness or growth of breasts, osteoporosis, anemia, cognitive reduction, muscle mass loss, weight gain, fatigue, elevated cholesterol and depression.
For male subjects administered 5-alpha-reductase inhibitors side effects are sexual in nature for example erectile dysfunction, decreased libido, reduced ejaculate and breast enlargement or tenderness. These drugs can also lower levels of Prostate-Specific Antigen (PSA) thereby interfering with the results of this analyte utilised to detect prostate cancer. Male and female subjects may also experience with spironolactone breast tenderness, menstrual irregularities (females only), fatigue, dizziness, confusion, nausea and vomiting, headache, hypotension, diarrhoea and possibly hyperkalemia. Cyproterone acetate can cause oligomenorrhea (females only), melasma, fluid retention, nausea and vomiting; this drug is also in rarer cases associated with liver hepatotoxicity and clotting disorders. Flutamide administration may lead to breast tenderness, gastrointestinal upset, hot flashes, and decreased libido; it has a serious potential side-effect of hepatotoxicity. Females taking combined oral contraceptives may experience metrorrhagia, nausea, vomiting, breast tenderness and headaches; and more rarely blood clots, myocardial infarctions, stroke, abnormal lipid indices, glucose intolerance and hypertension.
New innovative approaches are urgently needed at both the basic science and clinical levels to develop compositions and treatment regimens, which provide the beneficial effects of androgen and/or gonadotropins suppression or abrogation, without the deleterious side-effects associated with the current treatments for sex-hormone dependent diseases.
Tachykinins belong to a family of short peptides that are widely distributed in the mammalian central and peripheral nervous system (Bertrand and Geppetti, Trends Pharmacol. Sci. 17: 255-259 (1996)). They share the common C-terminal sequence Phe-Xaa-Gly-Leu-Met-NH2. The three major tachykinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB) with preferential affinity for respectively three distinct receptor subtypes, termed NK-1, NK-2, and NK-3.
Compounds showing selective affinity simultaneously to both NK-1 and NK-3 receptors namely dual NK-l/NK-3 receptor antagonists are being developed for the treatment of both schizophrenia and substance abuse disorders.
Prior to the present invention, however it has not been disclosed or suggested that a dual NK-l/NK-3 receptor antagonist according to the present invention would be useful in the treatment of sex-hormone dependent diseases in which decreased levels of androgens and gonadotropins are desired.
SUMMARY OF THE INVENTION:
The present invention relates to the novel use of dual NK-l/NK-3 receptor antagonists to achieve gonadotropin and/or androgen suppression in mammals. According to this invention, dual NK-l/NK-3 receptor antagonists are administered for the treatment of diseases which are caused by abnormal levels of androgens, particularly testosterone. The compounds described herein by reference are particularly useful according to this invention.
Thus, the solution provided by the present invention is the use of dual NK- l/NK-3 receptor antagonists in the treatment of sex-hormone dependent diseases.
Specifically, in a first aspect, the invention provides a method of treatment of sex-hormone dependent diseases comprising administering to a human in need thereof an effective amount of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
In a further aspect thereof, the invention provides the use of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases.
In a yet further aspect thereof, the invention provides dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases.
In a yet further aspect thereof, the invention provides a method for providing oral contraception, said method comprising administering to the patient an effective amount of dual NK-l/NK-3 receptor antagonists. In a further aspect of the invention there is provided the use of dual NK-l/NK-3 receptor antagonists for the production of a drug for oral contraception.
DETAILED DESCRIPTION OF THE INVENTION
Surprisingly, it has now been found that dual NK-l/NK-3 receptor antagonists are effective in suppressing gonadotropin and/or androgen production/secretion, specifically in suppressing the production of LH and/or testosterone in mammals. Suppression of gonadotropin production/secretion results in the suppression of androgen production/secretion. Thus, the instant invention is in a method of treatment of sex-hormone dependent diseases which are affected, or exacerbated by, elevated and/or abnormal levels of gonadotropins and/or androgens. Specifically, the invention relates to a method of suppressing gonadotropin and/or androgen blood levels by administering an effective amount of a dual NK- l/NK-3 receptor antagonist. The compounds defined herein exhibit the ability to suppress gonadotropin and/or androgen production, and in particular, are effective in reversibly lowering blood levels of LH and the androgen testosterone. DEFINITIONS
All numbers expressing quantities, percentages or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term "about."
It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the enumerated components. It will be clear to one of ordinary skill in the art that the use of the singular includes the plural unless specifically stated otherwise.
The term "sex hormone-dependent disease" as used herein means a disease which is exacerbated by, or caused by, excessive, inappropriate or unregulated sex hormone production.
Example of such diseases in men include but are not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hypertrichosis, male pattern baldness and in boys precocious puberty. Example of such diseases in women include but not limited to endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, hormone-dependent cancers (ovarian cancer, breast cancer), hyperandrogenism, hirsutism, hypertrichosis, female androgenetic alopecia, androgen dependent acne, seborrhoea, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with hyperplasia of luteinized theca cells in ovarian stroma), other manifestations of high intraovarian androgen concentrations (e.g. follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen- producing tumor (virilizing ovarian or adrenal tumor) and osteoporosis. In women other examples are pre-eclampsia and for both sexes, hidradenitis suppurativa and hot flushes.
As used herein "a dual NK-l/NK-3 receptor antagonist" refers to a compound that shows in a single molecule simultaneously affinity to both NK-1 and NK-3 receptors.
The term "androgen" is used herein to mean steroids that encourage the development of male sex characteristics and include the steroid derivatives of androstane including testosterone, dihydrotestosterone, androstenedione, and analogs.
As used herein, "gonadotropin suppression" refers to the reduction in the production or synthesis of one or more naturally occurring gonadotropins, including lutinizing hormone and follicle-stimulating hormone.
As used herein, "androgen suppression" refers to an effective amount of a dual NK-l/NK-3 receptor antagonist, which will cause a decrease in the in vivo levels of the androgen to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated androgen production.
As used herein, the term "hot flushes" is interchangeable with the term "hot flashes" and with the term "vasomotor symptoms" and intended to have the same meaning.
As used herein, the terms "treatment," "treating," and the like, refer to obtaining a desired pharmacologic, physiologic, dermatologic or cosmetic effect. The effect may be prophylactic in terms of completely or partially preventing a condition or disease or disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a condition or disease or disorder and/or adverse symptom or effect attributable to the condition or disease or disorder.
"Treatment," thus, for example, covers any treatment of a condition or disease in a mammal, particularly in a human, and includes: (a) preventing the condition or disease, disorder or symptom thereof from occurring in a subject which may be predisposed to the condition or disease or disorder but has not yet been diagnosed as having it; (b) inhibiting the condition or disease, disorder or symptom thereof, such as, arresting its development; and (c) relieving, alleviating or ameliorating the condition or disease or disorder or symptom thereof, such as, for example, causing regression of the condition or disease or disorder or symptom thereof.
As used herein, the term "effective amount" means that amount of a drug or a therapeutic agent or a pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher, clinician or veterinarian.
As used herein, "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition.
Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided. In addition, each excipient must of course be pharmaceutically-acceptable e.g. of sufficiently high purity.
As used herein "pharmaceutically acceptable salts" means salts suitable for medical applications having a pharmaceutically acceptable anion or cation.
In one embodiment, the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, abnormal puberty, uterine fibrosis, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian or adrenal tumor, or osteoporosis, comprising administering to a human in need thereof an effective amount of dual
NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
In one embodiment, the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis, or preeclampsia comprising administering to a human in need thereof an effective amount of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
In a further embodiment, the present invention provides dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, abnormal puberty, uterine fibrosis, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian or adrenal tumor, or osteoporosis, comprising administering to a human in need thereof an effective amount of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
In a further embodiment, the present invention provides dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis, or pre-eclampsia.
In a further aspect thereof, the invention provides the use of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, abnormal puberty, uterine fibrosis, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian or adrenal tumor, or osteoporosis.
In a further aspect thereof, the invention provides the use of a dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, , hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis, or pre-eclampsia.
In one embodiment, the sex-hormone dependent diseases according to the invention are selected from hirsutism, endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
Compounds for use herein include dual NK-l/NK-3 receptor antagonists as described in, and made according to WO2004056799, WO2004056805, WO2005002577, WO2005097794, WO2006013050, WO2007028654,
WO2008128891, WO2011131571 or WO2011023733 which are incorporated herein by reference in their entirety.
Preferred pyridine derivatives of WO2006013050 for use herein are as follows:
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy- ethoxy)-pyridin-3-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-l- hydroxymethyl-ethoxy)-pyridin-3-yl]-N-methyl-isobutyramide;
• (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6- (pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-N-methyl-isobutyramide;
· 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2- hydroxy-ethylsulfanyl)-pyridin-3-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- [2,3']bipyridinyl- 5-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l'-oxy- [2,3']bipyridinyl-5-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fIuoro-2-methyl-phenyl)-6-(3- hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-5'- hydroxymethyl-[2,3']bipyridinyl-5-yl]-N-methyl-isobutyramide;
· 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-2'- hydroxymethyl-[2,4']bipyridinyl-5-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l'- methanesulfonyl-l',2',3',6'-tetrahydro-[2)4']bipyridinyl-5-yl]-N-methyl- isobutyramide;
· 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l'- methanesulfonyl-l',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl-5-yl]-N-methyl- isobutyramide;
• (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l'- methanesulfonyl-l',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-5-yl]-N-methyl- isobutyramide; • (RS)-N-[l'-acetyl-4-(4-fluoro-2-methyl-phenyl)-l',2',3',4',5',6'-hexahydro- [2,3']bipyridinyl-5-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,6-dihydro-2H-thiopyran-4-yl)-4- (4-fluoro- 2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(l,l-dioxo-l,2,3,6-tetrahydro- lA6thiopyran-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(l,l-dioxo-hexahydro-lA6"thiopyran- 4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide; or pharmaceutically acceptable salts thereof.
Preferred pyrrolidine derivatives of WO2008128891 for use herein are as follows:
• rac-2-(3,5-bis-trifluoromethyl-phenyl)-N-[(3S,4R)-4-(4-chloro-phenyl)-l- (morpholine- 4-carbonyl)-pyrrolidin-3-yl]-N-methyl-isobutyramide;
• rac-2-(3,5-dichloro-phenyl)-N-[(3S,4R)-4-(4-fluoro-phenyl)-l-(morpholine-4- carbonyl)-pyrrolidin-3-yl] -N-methyl-isobutyramide;
• rac-2-(3,5-bis-trifluoromethyl-phenyl)-N-[(3S,4R)-4-(4-fluoro-2-methyl- phenyl)-l-(morpholine-4-carbonyl) -pyrrolidin-3-yl]-N-methyl- isobutyramide;
• rac-2-(3,5-bis-trifluoromethyl-phenyl)-N-[(3S,4R)-4-(4-fluoro-phenyl)-l-(4- methanesulfonyl-piperazine-l-carbonyl) -pyrrolidin-3-yl]-N-methyl- isobutyramide;
• rac-N-[(3S,4R)-l-(4-acetyl-piperazine-l-carbonyl)-4-(4-fluoro-phenyl) - pyrrolidin-3yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide;
• rac-2-(3,5-bis-trifluoromethyl-phenyl)-N-[(3S,4R)-l-(4-methanesulfonyl- piperazine-l-carbonyl)-4-phenyl-pyrrolidin-3-yl] -N-methyl-isobutyramide;
• rac-2-(3,5-dichloro-phenyl)-N-[(3S,4R)-4-(4-fluoro-phenyl)-l-(4- methanesulfonyl-piperazine-l-carbonyl) -pyrrolidin-3-yl] -N-methyl- isobutyramide;
• rac-2-(3,5-bis-trifluoromethyl-phenyl)-N-[(3S,4R)-4-(4-fluoro-2-methyl- phenyl)-l-(4- methanesulfonyl-piperazine-l-carbonyl)-pyrrolidin-3-yl] -N- methyl-isobutyramide;
• rac-N-[(3S,4R) -4-(4-chloro-phenyl) -l-(4-methanesulfonyl-piperazine-l- carbonyl)-pyrrolidin-3-yl] -2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide;
• rac-(3S,4R)-3-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]- methyl- amino}-4-(4-fluoro-phenyl)-pyrrolidine-l-carboxylic acid bis-(2- hydroxy-ethyl)-amide;
• rac-(3S,4R)-3-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl] - methyl- amino}-4-(4-fluoro-phenyl)-pyrrolidine-l-carboxylic acid (2-hydroxy- ethyl)-amide;
or pharmaceutically acceptable salts thereof.
Preferred pyrazolopyridine derivatives of WO2011131571 for use herein are as follows:
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-(l-ethyl-4-o-tolyl-lH-pyrazolo [3 ,4- b]pyridin-5-yl)-N-methyl-isobutyramide; • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-ethyl-4-(4-fluoro-2-methyl-phenyl)- 1 H-pyrazolo [3,4-b]pyridin-5-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-l-ethyl-l-H- pyrazolo [3, 4-b]pyridin-5-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-l-ethyl-lH- pyrazolo [3 ,4-]pyridin-5-yl]-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-(2,2-difluoro-ethyl)-4-(4-fluoro-2- methyl-phenyl)-lH-pyrazolo [3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- 1 - methyl- 1 H-pyrazolo [3 ,4- b]pyridin-5-yl] -N-methyl-isobutyramide;
• N-[l-benzyl-4-(4-fluoro-2-methyl-phenyl)-lH-pyrazolo[3,4-b]pyridin-5-yl]-2- (3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide;
• 2-(3 ,5-bis-trifluoromethyl-phenyl)-N-[l -ethyl-4-(4-fluoro-2-methoxy- phenyl)-lH-pyrazo lo [3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-3-fluoro-phenyl)-l-ethyl-l H-pyrazolo [3,4-b]pyridin-5 -yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-l-ethyl-lH- pyrazolo[3,4-b]pyridin-5 yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-l-ethyl- 1 H-pyrazolo [3, 4-b]pyridin-5 -yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-5-hydroxymethyl-phenyl)- l-ethyl-lH-pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-lH- pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• N-[l-acetyl-4-(4-fluoro-2-methyl-phenyl)-lH-pyrazolo[3,4-b]pyridin-5-yl]-2- (3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-lH- pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l-(2- methoxy-acetyl)-lH-pyrazolo [3 ,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-cyclopropanecarbonyl-4-(4-fluoro-2- methyl-phenyl)-lH-pyrazolo [3 ,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l methanesulfonyl-lH-pyrazolo[3,4-b]pyridin-5 -yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-dimethylsulfamoyl-4-(4-fluoro-2- methyl-phenyl)-lH- pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l- methanesulfonylmethyl-lH-pyrazolo[3,4-b]pyridin-5-yl] -N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-ethyl-4-(4-methyl-thiophen-3-yl)- lH-pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide; • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-thiophen-3-yl)-l-ethyl-lH- pyrazolo£3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3-fluoro-5-trifloromethyl-phenyl)-N-[l-ethyl-4-(4-fluoro-2-methyl- phenyl)-lH-pyrazolo[3,4- b]pyridin-5-yl] -N-methyl-isobutyramide ;or
• 2-(3,5-dichloro-phenyl)-N-[l-ethyl-4-(4-fluoro-2-methyl-phenyl)-lH- pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
or pharmaceutically acceptable salts thereof.
Particularly preferred compounds for use herein are
• 2-[3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxylmethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] - 3-pyridinyl}-N,2-dimethylpropanamide;
• (2R,3S 2-(3,5-bis-trifluoromethylphenyl N-[4-(4-fluoro-2-methyl-phenyl 6-(3-hydroxy-2-hydrox ymethyl- pyrrolidin-l-yl) -pyridin-3-yl] -N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l'- methanesulfonyl-l',2',3',6'-tetrahydro-[2)4']bipyridinyl-5-yl] -N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l'- methanesulfonyl-l',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl-5-yl] -N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(l,l-dioxo-l,2,3,6-tetrahydro- lA6thiopyran-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl] -N-methyl- isobutyramide;
• rac-N-[(3S,4R)-4-(4-chloro-phenyl) -l-(4-methanesulfonyl-piperazine-l- carbonyl)-pyrrolidin-3-yl] -2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-(2,2-difluoro-ethyl)-4-(4-fluoro-2- methyl-phenyl)-lH-pyrazolo[3,4-b]pyridin-5-yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l- methanesulfonylmethyl-lH-pyrazolo[3,4-b]pyridin-5 -yl]-N-methyl- isobutyramide; or pharmaceutically acceptable salts thereof.
Particularly preferred compounds according to the invention are
• 2-[3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] - 3-pyridinyl}-N,2-dimethylpropanamide (formula A);
Figure imgf000012_0001
(A) • (2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- 6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-l-yl)-pyridin-3-yl] -N-methyl- isobutyramide (formula B);
Figure imgf000013_0001
or pharmaceutically acceptable.salt or crystalline forms thereof.
Methods for preparing compound of formula A, salts thereof and its crystalline forms are described in WO2007028654 and WO2011023733 respectively, which methods are incorporated herein by reference.
Specifically WO2011023733 discloses compound of formula A in a crystalline anhydrate form (Form 1), having certain characteristic 2 theta angles occurring at 4.3+0.1, 7.9+0.1, 9.8+0.1, 10.7+0.1, 10.8+0.1, 13.3+0.1, 14.0+0.1, 15.1+0.1degrees, which correspond respectively to d-spacing at 20.4, 11.1, 9.0, 8.3, 8.2, 6.6, 6.3 and 5.9 Angstroms (A).
Methods for preparing the compound of formula B or salt thereof are described in WO2005002577, which methods are incorporated herein by reference.
In a further embodiment, the invention provides
2- [3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(l//)-yl] -
3- pyridinyl}-N,2-dimethylpropanamide or
(2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6- (3-hydroxy-2-hydroxymethyl-pyrrolidin-l-yl)-pyridin-3-yl] -N-methyl- isobutyramide; pharmaceutically acceptable salts or crystalline forms thereof for use for the treatment of sex-hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis, or pre-eclampsia.
In a further embodiment, the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, breast cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis or pre-eclampsia which comprises administering to a human in need thereof an effective amount of the compounds:
• 2-[3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6-
[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] - 3-pyridinyl}-N,2-dimethylpropanamide;
· (2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-l-yl)-pyridin-3-yl] -N-methyl isobutyramide; or pharmaceutically acceptable salts or crystalline forms thereof. In a further embodiment, the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of androgen dependent hirsutism, female androgenetic , endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes, which comprises administering to a human in need thereof an effective amount comprising administering to a human in need thereof an effective amount of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
In a further embodiment, the invention provides a method of treatment of sex- hormone dependent diseases selected from the group consisting of androgen dependent hirsutism, female androgenetic endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes, which comprises administering to a human in need thereof an effective amount of 2-[3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] -3- pyridinyl}-N,2-dimethylpropanamide; (2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6- (3-hydroxy-2-hydroxymethyl-pyrrolidin-l-yl)-pyridin-3-yl] -N-methyl- isobutyramide;or pharmaceutically acceptable salts thereof. In one embodiment, the compound according to the invention is 2-[3,5-
Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(l//)-yl] -3-pyridinyl}- N,2-dimethylpropanamide or crystalline anhydrate forms thereof for use in the treatment of hirsutism, endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
In a yet further embodiment, the compound according to the invention is 2- [3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] -3-pyridinyl}- N,2-dimethylpropanamide as anhydrous crystalline Form 1 for use in the treatment of endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
In a yet further embodiment, the compound according to the invention is 2- [3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl] -3-pyridinyl}- N,2-dimethylpropanamide as anhydrous crystalline Form 1 for use in the treatment of hot flushes. Owing to their activity on the gonadotropin-releasing hormone (GnRH) pathway, dual NK-l/NK-3 receptor antagonists can be used alone or in combination with estrogen and progestin as contraceptives.
Thus, in a further aspect, the present invention provides a method for providing oral contraception, said method comprising administering to the patient an effective amount of dual NK-l/NK-3 receptor antagonists.
In a further aspect of the invention there is provided the use of dual NK-l/NK- 3 receptor antagonists for the production of a drug for oral contraception.
Compounds for use for oral contraception include dual NK-l/NK-3 receptor antagonists as described in, and made according to WO2004056799, WO2004056805, WO2005002577, WO2005097794, WO2006013050,
WO2007028654, WO2008128891, WO2011131571, WO2011023733 which are incorporated herein by reference in their entirety.
Preferred pyridine derivatives of WO2006013050 for use for oral contraception are those disclosed on pages 8 and 9, lines 10-45 and lines 1-15 respectively of the present specification. Preferred pyrrolidine derivatives of WO2008128891 for use for oral contraception are those disclosed on page 9, lines 15-43 of the present specification.
Preferred pyrazolopyridine derivatives of WO201131571 for use for oral contraception are those disclosed from page 9, line 47 to page 11, line 6 of the present specification.
Particularly preferred compounds for use for oral contraception are
• 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH)-yl]-3- pyridinyl}-N,2-dimethylpropanamide(Formula A);
Figure imgf000016_0001
(2R,3S 2-(3,5-bis-trifluoromethylphenyl N-[4-(4-fluoro-2-methyl-phi 6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-l-yl)-pyridin-3-yl]-N-methyl- isobutyramide (Formula B);
Figure imgf000016_0002
(B)
or pharmaceutically acceptable salt or crystalline forms thereof.
The present invention further provides a pharmaceutical composition comprising a dual NK-l/NK-3 receptor antagonist or a compound described above, a pharmaceutically acceptable salt or crystalline forms thereof, and a pharmaceutically acceptable carrier.
Thus, in one embodiment, the invention provides a pharmaceutical composition comprising a dual NK-l/NK-3 receptor antagonist or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in the treatment of sex hormone-dependent diseases.
In a further embodiment, the invention provides a pharmaceutical composition comprising 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2- methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l- c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide or crystalline anhydrate forms thereof and a pharmaceutically acceptable carrier for use in the treatment of of sex hormone-dependent diseases.
In a further embodiment, the invention provides a pharmaceutical composition comprising 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2- methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l- c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide or crystalline anhydrate forms thereof and a pharmaceutically acceptable carrier for use in the treatment hirsutism, endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
In a further embodiment, the present invention provides a drug containing a dual NK-l/NK-3 receptor antagonist and a pharmaceutically acceptable carrier.
In a yet further embodiment, the present invention provides a drug containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)
-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(lH) yl]-3-pyridinyl}-N,2-dimethylpropanamide or a pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate pharmaceutically acceptable carrier. It may contain a diluent, binder, filler, disintegrant, flavoring agent, colouring agent, lubricant or preservative in conventional manner.
These conventional excipients may be employed for example as in the preparation of compositions of known agents for treating the conditions.
Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarian fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release ofthe active ingredient.
Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatine, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk.
Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatine containing the compound, if desired with a carrier or other excipients.
Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatine, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavoring or colouring agents.
The compounds of this invention may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e. g. sterile pyrogenic-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
The compounds of this invention may also be administered by inhalation, via the nasal or oral routes. Such administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
Preferred spray formulations comprise micronized compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles. Preferably, the compound particle size is from about 2 to 10 microns.
A further mode of administration of the compounds of the invention comprises transdermal delivery utilizing a skin-patch formulation. A preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient. For a constant rate of percutaneous absorption, pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.
The manufacture of the pharmaceutical compositions according to the present subject matter may be performed according to methods known in the art. Commonly known and used pharmaceutically acceptable auxiliaries as well as further suitable diluents, flavourings, sweetening agents, colouring agents etc. may be used, depending on the intended mode of administration as well as particular characteristics of the active compound to be used, such as solubility, bioavailability etc.
Any non-toxic, inert, and effective topical, oral, etc. pharmaceutically acceptable carrier may be used to formulate the compositions described herein.
Well-known carriers used to formulate other topical therapeutic compositions for administration to humans are useful in these compositions. Examples of these components that are well known to those of skill in the art are described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association)
International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the "Inactive Ingredient Guide", U.S. Food and Drug Administration (FDA) Center for Drug.
As mentioned above, the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration. An effective dose will generally contain from 1 mg to 250 mg and preferably will contain from 10 mg to 220 mg, in particular 30 mg to 200 mg.
The composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 30 mg to 200 mg.
Alternatively the unit dose will contain from 10 to 100 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily doses.
No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention.
The compounds of the invention or pharmaceutically acceptable salts thereof and the other pharmaceutically active agent(s) may be administered together in a fix combination or separately (i.e. non fix combination).
When administered separately, this may occur separately or sequentially in any order and treatment regimens in which the agents are not necessarily administered by the same route of administration may also occur. The amounts of the compound inventions or pharmaceutically acceptable salts thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
Examples of suitable therapeutic agents which may be used in combination of the compounds of the invention or pharmaceutically acceptable salts thereof include agonists of Gonadotropin-releasing hormone (GnRH) such as nafarelin, buserelin, goserelin and leuprorelin; antagonists of the Gonadotropin-releasing hormone (GnRH) such as degarelix, ganirelix, cetrorelix, abarelix and elagolix; 5- alpha-reductase inhibitors such as dutasteride and finasteride; combined androgen receptor antagonists/ 5-alpha-reductase inhibitors such as spironolactone; anti-androgens such as cyproterone acetate and flutamide; combined (estrogen with a progestin) oral contraceptives such as estrogen with either norgestimate, or norethindrone, or drospirenone; progesterone receptor modulators such as ulipristal acetate. BIOLOGICAL DATA
The anti-androgenic effects of the compounds useful herein are determined bythe following clinical studies on human volunteers which demonstrate testosterone lowering effects.
Example 1
2-[3,5-Bis(trifluoromethyl)phenyl] -N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)- -(hydroxymethyl)hexahydropyrazino[2,l-c] [l,4] oxazin-8(l//)-yl] -3-pyridinyl}- N,2-dimethylpropanamide(hereinafter Compound A) was administered both as single and repeat ascending doses in male human volunteers (HV) and the effect of Compound A on the levels of testosterone was assessed
1. Single ascending dose studies
Male HVs received in a single-blinded, randomised fashion, single ascending oral doses of placebo or Compound A ranging from 10 to 250 mg as suspensions.
Free and total testosterone serum levels were measured at Day-1, then 24 hours after each dose and at follow-up (7-14 days after Compound A dose). Resulting HV serum testosterone levels (free and total) were determined as described in Table 1.
Table 1. Free and total testosterone levels in HVs from single ascending dose study
Figure imgf000021_0001
Key: SD =standard deviation
As shown in Table 1 clinically relevant reductions in free and total testosterone levels are evident within 24 h following administration of Compound
A. At doses of ≥160 mg the decreases range from between 35% and 43%. Testosterone levels recovered to baseline levels at follow-up (7-14 days after the last dose of Compound A). 2. Repeat ascending dose of Compound A
Part A of this study comprised 3 cohorts that investigated the safety, tolerability and PK of escalating multiple daily doses of Compound A. Information on these cohorts is as follows: Cohorts 1 and 2 received Compound A for 14 days; with a follow-up 7 to 14 days after their last dose. Testosterone levels in both cohorts were measured pre-dose on Day 1, on Day 15 and at follow-up.
Cohort 3 also received Compound A over a repeat treatment period of 14 days; with a follow-up 7-14 days after their last dose. Testosterone levels were measured in this cohort pre-dose on Day-1 and pre-dose on Day 14, and at follow- up.
Resulting HV serum testosterone levels (free and total) were determined as described in Table 2.
Table 2. Free and total testosterone levels in HVs from repeat dose study
Figure imgf000022_0001
Key: SD = standard deviation; * two subjects in the 90 mg dose arm were dose reduced between baseline and Day 5 and have been removed from the analysis to avoid confounding the data; ** two subjects in the 200 mg dose arm were dose-reduced between baseline and Day 14 (data removed)
Clinically relevant reductions in free and total testosterone levels were again evident after repeat dosing with Compound A. At doses of 200 mg after 14 days; the decreases ranged from between 43% and 45%; consistent with the values observed after 24 hours in the single ascending dose study. Testosterone levels recovered to baseline levels at follow-up (7-14 days after the last dose of 200 mg Compound A).
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

1. Dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for use in the treatment of sex-hormone dependent diseases.
2. Use of dual NK-l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of sex-hormone dependent diseases.
Use according to claims 1 or 2, wherein the dual NK-l/NK-3 receptor antagonist is selected from:
• 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxylmethyl)hexahydropyrazino[2,l-c] [l,4] oxazin- 8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide;
• (2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro-2-methyl- phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-l-yl)-pyridin-3- yl] -N-methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- l'-methanesulfonyl-l',2',3',6'-tetrahydro-[2)4']bipyridinyl-5-yl]-N- methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- l'-methanesulfonyl-l',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl-5-yl]-N- methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(l,l-dioxo-l,2,3,6-tetrahydro- lA6thiopyran-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N- methyl-isobutyramide;
• rac-N-[(3S,4R)-4-(4-chloro-phenyl)-l-(4-methanesulfonyl-piperazine- l-carbonyl)-pyrrolidin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-(2,2-difluoro-ethyl)-4-(4- fluoro-2-methyl-phenyl)-lH-pyrazolo[3,4-b]pyridin-5-yl] -N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-l- methanesulfonylmethyl-lH-pyrazolo[3,4-b]pyridin-5-yl] -N-methyl- isobutyramide; or pharmaceutically acceptable salts thereof.
Use according to any one of claims 1 to 3, wherein the dual NK-l/NK-3 receptor antagonist is 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-
2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l- c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide of formula (A) or crystalline anhydrate forms thereof.
Figure imgf000025_0001
Use according to any one of claims 1 to 4, wherein the dual NK-l/NK-3 receptor antagonist is 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro- 2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino
[2,l-c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide as crystalline anhydrate Form 1.
Use according to any one of claims 1 to 5, wherein the sex-hormone dependent disease is selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis, or pre-eclampsia.
Use according to any one of claims 1 to 6, wherein the sex-hormone dependent disease is endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS), or hot flushes.
A method of treatment of sex-hormone dependent diseases comprising administering to a human in need thereof an effective amount of dual NK- l/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof.
A method according to claim 8, wherein the dual NK-l/NK-3 receptor antagonist is selected from:
• 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6- [(7S,9aS)-7-(hydroxylmethyl)hexahydropyrazino[2,l-c] [l,4] oxazin- 8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide;
• 2R,3S)-2-(3,5-bis-trifluoromethylphenyl)-N-[4-(4-fluoro-2-methyl- phenyl)-6-(3-hydroxy-2-hydrox ymethyl-pyrrolidin-l-yl) -pyridin-3- yl] -N-methyl-isobutyramide; • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- l'-methanesulfonyl-l',2',3',6'-tetrahydro-[2)4']bipyridinyl-5-yl]-N- methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- l'-methanesulfonyl-l',2',3'4',5',6'-hexahydro-[2,4']bipyridinyl-5-yl]-N- methyl-isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(l,l-dioxo-l, 2,3,6- tetrahydro-lA6thiopyran-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin- 3-yl]-N-methyl-isobutyramide;
• rac-N-[(3S,4R)-4-(4-chloro-phenyl)-l-(4-methanesulfonyl-piperazine- l-carbonyl)-pyrrolidin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[l-(2,2-difluoro-ethyl)-4-(4- fluoro-2-methyl-phenyl)-lH-pyrazolo [3,4-b]pyridin-5-yl]-N-methyl- isobutyramide;
• 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)- l-methanesulfonylmethyl-lH-pyrazolo[3,4-b]pyridin-5-yl]-N-methyl- isobutyramide; or pharmaceutically acceptable salts thereof.
10. A method according to claims 8 or 9, wherein the dual NK-l/NK-3 receptor antagonist is 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro- 2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,l- c] [l,4]oxazin-8(lH)-yl]-3-pyridinyl}-N,2-dimethylpropanamide of formula (A) or crystalline anhydrate forms thereof.
11. A method according to any one of claims 8 to 10, wherein the dual NK- l/NK-3 receptor antagonist is 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4- fluoro-2-methylphenyl)-6-[(7S,9aS)-
7 (hydroxymethyl)hexahydropyrazino [2, 1 -c] [1,4] oxazin-8 (1 H) -yl] -3 - pyridinyl}-N,2-dimethylpropanamide of formula (A) as crystalline anhydrate Forml.
12. A method according to any one of claims 8 to 11, wherein the sex- hormone dependent disease is selected from the group consisting of benign prostatic hyperplasia (BPH), metastatic prostatic carcinoma, testicular cancer, breast cancer, androgen dependent acne, seborrhoea, hirsutism, hypertrichosis, male pattern baldness, female androgenetic alopecia, endometriosis, adenomyosis, abnormal puberty, uterine fibrosis, heavy menstrual bleeding, ovarian cancer, hyperandrogenism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome, ovarian hyperthecosis, hidradenitis suppurativa, hot flushes and precocious puberty in boys, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility virilizing ovarian, adrenal tumor, osteoporosis, or pre-eclampsia.
13. A method according to any one of claims 8 to 12, wherein the disease is selected from the group consisting of hirsutism, endometriosis, adenomyosis, uterine fibrosis, heavy menstrual bleeding, polycystic ovary syndrome (PCOS) and hot flushes.
PCT/EP2016/060945 2015-05-18 2016-05-16 Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases Ceased WO2016184829A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
JP2017554079A JP6902682B2 (en) 2015-05-18 2016-05-16 NK-1 / NK-3 receptor dual antagonist for the treatment of sex hormone-dependent diseases
MX2017012720A MX377052B (en) 2015-05-18 2016-05-16 DUAL NEUROCININ-1 (NK-1) / NEUROCININ-3 (NK-3) RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SEX HORMONE-DEPENDENT DISEASES.
CN201680025842.XA CN107635557A (en) 2015-05-18 2016-05-16 Dual NK‑1/NK‑3 receptor antagonists for the treatment of sex hormone-dependent diseases
BR112017024852-2A BR112017024852B1 (en) 2015-05-18 2016-05-16 USES OF A DUAL NK-1/NK-3 RECEPTOR ANTAGONIST COMPOUND AND A PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND FOR THE TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
ES16723107T ES2753539T3 (en) 2015-05-18 2016-05-16 NK-1 / NK-3 receptor antagonist for the treatment of hot flashes
AU2016264034A AU2016264034B2 (en) 2015-05-18 2016-05-16 Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
RU2017134908A RU2743206C2 (en) 2015-05-18 2016-05-16 Double neurokinin-1/neurokinin-3 receptor antagonists for treating sex hormone dependent diseases
LT16723107T LT3297631T (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
CN202210025858.8A CN114306335A (en) 2015-05-18 2016-05-16 Dual NK-1/NK-3 receptor antagonists for the treatment of sex hormone-dependent diseases
KR1020177036005A KR102704783B1 (en) 2015-05-18 2016-05-16 Dual NK-1/NK-3 receptor antagonist for the treatment of sex-hormone dependent disorders
RS20191505A RS59608B1 (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
CA2984591A CA2984591A1 (en) 2015-05-18 2016-05-16 Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
DK16723107T DK3297631T3 (en) 2015-05-18 2016-05-16 NK-1 / NK-3 receptor antagonist for the treatment of hot flushes
HRP20192132TT HRP20192132T1 (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
EP16723107.5A EP3297631B1 (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
CN202210026259.8A CN114272242A (en) 2015-05-18 2016-05-16 Dual NK-1/NK-3 receptor antagonists for the treatment of sex hormone dependent diseases
PL16723107T PL3297631T3 (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
CN202210025860.5A CN114306347A (en) 2015-05-18 2016-05-16 Dual NK-1/NK-3 receptor antagonists for the treatment of sex hormone dependent diseases
EP19186140.0A EP3574907B1 (en) 2015-05-18 2016-05-16 A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases
SI201630503T SI3297631T1 (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
SM20190719T SMT201900719T1 (en) 2015-05-18 2016-05-16 Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
CY20191101087T CY1122180T1 (en) 2015-05-18 2019-10-17 NK-1/NK-3 RECEPTOR ANTAGONIST FOR THE THERAPEUTIC TREATMENT OF HOT HOTS
AU2020201074A AU2020201074B2 (en) 2015-05-18 2020-02-14 Dual NK-1/NK-3 Receptor Antagonists For The Treatment Of Sex-Hormone-Dependent Diseases
LTPA2026506C LTPA2026506I1 (en) 2015-05-18 2026-01-29
FIC20260003C FIC20260003I1 (en) 2015-05-18 2026-02-04 Organoleptically active agent or a pharmaceutically acceptable salt thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562162870P 2015-05-18 2015-05-18
US62/162,870 2015-05-18

Publications (1)

Publication Number Publication Date
WO2016184829A1 true WO2016184829A1 (en) 2016-11-24

Family

ID=56008636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/060945 Ceased WO2016184829A1 (en) 2015-05-18 2016-05-16 Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases

Country Status (23)

Country Link
US (4) US10195205B2 (en)
EP (2) EP3574907B1 (en)
JP (1) JP6902682B2 (en)
KR (1) KR102704783B1 (en)
CN (4) CN114272242A (en)
AU (2) AU2016264034B2 (en)
BR (1) BR112017024852B1 (en)
CA (1) CA2984591A1 (en)
CY (1) CY1122180T1 (en)
DK (1) DK3297631T3 (en)
ES (1) ES2753539T3 (en)
FI (1) FIC20260003I1 (en)
HR (1) HRP20192132T1 (en)
HU (1) HUE047732T2 (en)
LT (2) LT3297631T (en)
MX (2) MX377052B (en)
PL (1) PL3297631T3 (en)
PT (1) PT3297631T (en)
RS (1) RS59608B1 (en)
RU (1) RU2743206C2 (en)
SI (1) SI3297631T1 (en)
SM (1) SMT201900719T1 (en)
WO (1) WO2016184829A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2021094247A1 (en) 2019-11-15 2021-05-20 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
US20230277518A1 (en) * 2020-07-30 2023-09-07 Acer Therapeutics Inc. Nk receptor antagonists for cancer patients
EP4431512A1 (en) * 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025261856A1 (en) 2024-06-18 2025-12-26 Bayer Consumer Care Ag Improved process for producing an elinzanetant precursor
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc A combination for use in treating heavy menstrual bleeding associated with uterine fibroids
BR112020021276A2 (en) * 2018-04-19 2021-01-26 Abbvie Inc. methods of treating heavy menstrual bleeding
CA3188730A1 (en) * 2020-08-12 2022-02-17 Christopher Barnes Methods and compositions for treating polycystic ovary syndrome
WO2023147135A1 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2005097774A1 (en) * 2004-04-08 2005-10-20 Janssen Pharmaceutica N.V. Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282721B6 (en) * 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Non-peptide NK3 antagonists, their production method, pharmaceuti cal preparations containing them and their use
RU2181598C2 (en) * 1994-07-22 2002-04-27 Дзе Медикал Колледж оф Хэмптон Роудс Recovery of tonic secretion of ovarian estrogen for prolonged therapeutic schemes
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
DE60129562T2 (en) 2000-06-12 2008-04-17 The University Of Rochester Method of treating hot flashes by using a tachykinin receptor antagonist
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
MXPA05000196A (en) * 2002-07-03 2005-06-06 Schering Corp 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough.
US7514424B2 (en) 2002-12-23 2009-04-07 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Substituted diaza-spiro-(4,5)-Decane derivatives and their use as neurokinin antagonists
JP2007537233A (en) 2004-05-12 2007-12-20 ファイザー・プロダクツ・インク Piperidine derivatives as NK1 and NK3 antagonists
DE102004033902A1 (en) 2004-07-14 2006-02-16 Zentaris Gmbh New tetrahydrocarbazole compounds are neurokinin-1 receptor antagonists useful to treat or prevent e.g. pubertas praecox, hirsutism, polycystic ovary syndrome, hormone dependent neoplastic diseases and Alzheimer's disease
WO2006013205A1 (en) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP1928886B1 (en) 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders
AU2006297414A1 (en) * 2005-09-29 2007-04-12 Wyeth 1- (1H- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (VMS)
JP2010537623A (en) * 2007-03-27 2010-12-09 クリストファー ホーヴェンス Methods and compositions for treating prostate cancer
WO2008128891A1 (en) 2007-04-20 2008-10-30 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
US8415884B2 (en) 2009-09-08 2013-04-09 Tokyo Electron Limited Stable surface wave plasma source
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
MX2012013855A (en) * 2010-05-28 2013-04-08 Univ Texas Oligo-benzamide compounds and their use.
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (en) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín USE OF ANTIBODIES AGAINST NK1, NK2 AND / OR NK3 RECEPTORS, TO PRODUCE APOPTOSIS IN TUMOR CELLS AND TO MODIFY STRAMA, IMMUNITY AND INTRA AND PERITUMORAL VASCULARIZATION, AS TREATMENT OF CANCER.
US20150272927A1 (en) 2012-12-03 2015-10-01 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
US10774091B2 (en) * 2018-03-14 2020-09-15 KaNDy Therapeutics Limited Soft gelatin capsule formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2005097774A1 (en) * 2004-04-08 2005-10-20 Janssen Pharmaceutica N.V. Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CATERINA BISSANTZ ET AL: "Identification of a Crucial Amino Acid in the Helix Position 6.51 of Human Tachykinin Neurokinin 1 and 3 Receptors Contributing to the Insurmountable Mode of Antagonism by Dual NK 1 /NK 3 Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 11, 14 June 2012 (2012-06-14), US, pages 5061 - 5076, XP055234123, ISSN: 0022-2623, DOI: 10.1021/jm2017072 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7433252B2 (en) 2018-03-14 2024-02-19 キャンディ・セラピューティクス・リミテッド Novel pharmaceutical formulations containing dual NK-1/NK-3 receptor antagonists
US12264164B2 (en) 2018-03-14 2025-04-01 KaNDy Therapeutics Limited Method of treatment of symptoms of menopause
JP2021517590A (en) * 2018-03-14 2021-07-26 キャンディ・セラピューティクス・リミテッド A novel pharmaceutical product containing an NK-1 / NK-3 receptor double antagonist
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
US11767328B2 (en) 2018-03-14 2023-09-26 KaNDy Therapeutics Limited Method of treatment of symptoms of menopause
TWI874486B (en) * 2019-11-15 2025-03-01 英商卡恩廸醫療有限公司 New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
WO2021094247A1 (en) 2019-11-15 2021-05-20 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
US12473260B2 (en) 2019-11-15 2025-11-18 KaNDy Therapeutics Limited Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
US20230277518A1 (en) * 2020-07-30 2023-09-07 Acer Therapeutics Inc. Nk receptor antagonists for cancer patients
EP4431512A1 (en) * 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2024188935A1 (en) * 2023-03-16 2024-09-19 Bayer Consumer Care Ag Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025261856A1 (en) 2024-06-18 2025-12-26 Bayer Consumer Care Ag Improved process for producing an elinzanetant precursor
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Also Published As

Publication number Publication date
RU2743206C2 (en) 2021-02-16
JP6902682B2 (en) 2021-07-14
JP2018515445A (en) 2018-06-14
AU2016264034B2 (en) 2020-03-05
EP3297631B1 (en) 2019-09-04
FIC20260003I1 (en) 2026-02-04
AU2020201074B2 (en) 2021-07-29
MX2020011668A (en) 2021-01-15
US20260014166A1 (en) 2026-01-15
DK3297631T3 (en) 2019-11-11
US10195205B2 (en) 2019-02-05
EP3297631A1 (en) 2018-03-28
KR102704783B1 (en) 2024-09-10
PL3297631T3 (en) 2020-03-31
RU2017134908A3 (en) 2019-10-23
MX377052B (en) 2025-03-07
AU2016264034A1 (en) 2017-10-26
HUE047732T2 (en) 2020-05-28
CN114306335A (en) 2022-04-12
CA2984591A1 (en) 2016-11-24
CY1122180T1 (en) 2020-11-25
PT3297631T (en) 2019-10-10
SMT201900719T1 (en) 2020-01-14
CN107635557A (en) 2018-01-26
US20210128574A1 (en) 2021-05-06
AU2020201074A1 (en) 2020-03-05
CN114272242A (en) 2022-04-05
BR112017024852B1 (en) 2023-10-31
EP3574907C0 (en) 2023-08-23
EP3574907A1 (en) 2019-12-04
RS59608B1 (en) 2020-01-31
CN114306347A (en) 2022-04-12
LT3297631T (en) 2019-10-25
US20160339037A1 (en) 2016-11-24
SI3297631T1 (en) 2019-12-31
HRP20192132T1 (en) 2020-02-21
RU2017134908A (en) 2019-06-18
ES2753539T3 (en) 2020-04-13
BR112017024852A2 (en) 2018-08-07
MX2017012720A (en) 2018-02-09
EP3574907B1 (en) 2023-08-23
US20210236506A1 (en) 2021-08-05
KR20180004815A (en) 2018-01-12
LTPA2026506I1 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
AU2020201074B2 (en) Dual NK-1/NK-3 Receptor Antagonists For The Treatment Of Sex-Hormone-Dependent Diseases
EP1146873B1 (en) Anti-androgens and methods for treating disease
AU2002243411B2 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
MXPA04009455A (en) Enhancement of endogenous gonadotropin production.
AU2003210757A1 (en) Method of hormonal therapy
MXPA04011687A (en) Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm.
HK40018297A (en) An nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases
HK40063438A (en) Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
HK40073098A (en) Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
HK40064538A (en) Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
BR122023013023B1 (en) USES OF A DUAL NK-1/NK-3 RECEPTOR ANTAGONIST COMPOUND FOR THE TREATMENT OF VASOMOTOR SYMPTOMS
JP2024542205A (en) Methods and compositions for treating cancer
CZ20031349A3 (en) Combined treatment of estrogen-dependent diseases
WO2006013205A1 (en) Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20190192485A1 (en) Dosage regimen for the treatment of endometriosis
TW200902029A (en) Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in BRCA mediated diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16723107

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/012720

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2017554079

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016264034

Country of ref document: AU

Date of ref document: 20160516

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2984591

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20177036005

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017134908

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017024852

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017024852

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171121